Ginger S. Johnson, PhD
Chief Executive Officer
Ginger participates in and manages core assessment and strategic consulting projects, with special emphasis on CNS-associated therapeutic categories. Her background spans both the science and business of healthcare, ranging from basic scientific research to private equity investment and corporate development.
Ginger was Vice President, Corporate Development at Skila, where she was responsible for the identification and execution of strategic partnerships and, with an executive team, for the definition of corporate strategy. As the Director of Life Science Research at Chase Capital Partners (now JP Morgan Partners), a $25 billion global private equity firm, Ginger's research and investment activities focused on high growth opportunities in new and emerging areas within the pharmaceutical, biotechnology, medical device, and eHealth industries.
Ginger was Associate Director of the Center for Biotechnology at Northwestern University, where she helped to develop an innovative graduate program that combines the science and business of biotechnology. She spent eight years in basic and applied scientific research, primarily in the field of Alzheimer's disease, at the NIH and at Molecular Geriatrics, a start-up biotechnology company. She joined Defined Health in 2001.
Ginger has published 14 peer-reviewed articles, presented over 20 abstracts, and has been issued three patents. She earned her Bachelor of Science degree in Molecular Biology from University of Tennessee, a Doctorate in Genetics from George Washington University in Washington, DC, and has completed graduate studies at the Kellogg Graduate School of Management at Northwestern University.
- Supportive Neurology: Valuing Increased Function and Improved QoL in Treatment of Non-Core Symptoms of Neurological Disease
- Neurodegenerative disorders: Are we finally scaling the wall?
- Aducanumab: Hype, or Headway for the Alzheimer’s Amyloid Hypothesis?
- Migraine Prophylaxis: The Race is On
- Addressing Cognitive Deficits Across CNS Disorders: Potential to Improve Overall Outcomes and QoL
- CNS Orphans and Disease Subsegments: The Road Less Traveled